SUMMARY Pulmonary hypertension in systemic lupus erythematosus (SLE) in the absence of chronic parenchymal lung disease or pulmonary emboli is rare. We report such a case with an acute and rapidly progressive onset of symptoms in a patient who had started taking the contraceptive pill eight months previously.
A 22-year-old woman presented with a three-week history of increasing dyspnoea, pleuritic pain, and a skin rash. Three years previously she had an isolated episode of acute arthritis affecting some of the small joints of the hands and feet, which terminated spontaneously after one week. She remained well and had a normal first pregnancy, after which she started taking the contraceptive pill Eugynon 30 (ethinyloestradiol 30 gg, levonorgestrel 250 Rg) for the first time.
Nine months later she was admitted to hospital looking extremely ill, dyspnoeic, centrally cyanosed, pyrexic, and she had a widespread vasculitic rash. Marked right ventricular hypertrophy and failure were evident, and on auscultation there was a loud pericardial rub.
Haematological Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill 267 which might explain the frequency of occurrence of Raynaud's phenomenon in reported cases, though this feature was absent in our patient.
What role did the contraceptive pill play in this case? Our patient was well throughout a normal pregnancy and is therefore unlikely to have had significant pulmonary hypertension before starting the contraceptive pill. To account, though, for the degree of right ventricular hypertrophy at presentation, the onset of pulmonary hypertension must have occurred shortly after starting the contraceptive pill. This is consistent with the findings of Jungers et al.3 who showed a flare up incidence of 43% in patients with SLE within three months of starting oestrogens.
Thus it seems probable that the contraceptive pill has initiated this episode of pulmonary hypertension in a patient with SLE. There are no similar previously reported cases.
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